Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.83 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.66 |
| ▸ | KIT | P10721 | 1/20 | 0.66 |
| ▸ | FLT1 | P17948 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2855503 | 1.00 | KDR (0.83) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2859520 | 1.00 | KDR (0.83) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2864026 | 0.91 | KDR (1.00) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2868067 | 0.90 | KDR (1.00) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2864825 | 0.90 | KDR (0.97) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2856490 | 0.86 | KDR (0.73) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2868236 | 0.83 | KDR (0.81) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2871059 | 0.83 | KDR (0.79) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2855384 | 0.82 | KDR (1.00) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2859597 | 0.82 | KDR (0.82) | KDRPDGFRBKITFLT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513818-B1 | HETEROCYCLIC INHIBITORS OF VEGFR-2 KINASES | BRISTOL MYERS SQUIBB CO (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7547711-B2 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7084160-B2 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060135576-A1 | Heterocyclic inhibitors of kinases | BORZILLERI ROBERT M | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135576-A1 | Heterocyclic inhibitors of kinases | FGFR1, FLT1, FGFR2 | KDR 7/4885PDGFRB 27/4885KIT 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.